At page 47, line 28, please delete "(SEQ ID NO:19)" and insert therein --(SEQ ID NOs:14

and 19/--.

At page 49, Line 14, please delete "(SEQ ID NO:25)" and insert therein --(SEQ ID NOs:88

and/25)--.

At page 50, line 19, please delete "(SEQ ID NO:28)" and insert therein --(SEQ ID NOs:26

and 28)--

At page 55, line 21, please delete "(SEQ ID NO:47)" and insert therein --(SEQ ID

NO:48)--.

Remarks

The specification has been amended to correct obvious typographical errors. These amendments add no new matter.

The application also has been amended to add a Sequence Listing which contains nucleotide and amino acid sequences disclosed in the specification. Further, the specification has been amended to accurately indicate which sequences in the specification corresponded to sequences disclosed in the accompanying Sequence Listing. Support for the individual sequences in the Sequence Listing can be found throughout the specification where each sequence is disclosed and referred to by SEQ ID NO.

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

Applicants respectfully request that the Sequence Listing submitted herewith be entered into the captioned application.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Stephen G. Whiteside Attorney for Applicants Registration No. 42,224

Date: 4/14

1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005-3934 (202) 371-2600

Prel-Amend.wpd